What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Silvio E. Inzucchi mostly deals with Diabetes mellitus, Internal medicine, Type 2 diabetes, Endocrinology and Intensive care medicine.
The various areas that Silvio E. Inzucchi examines in his Diabetes mellitus study include Cardiology, Adverse effect, Surgery and Emergency medicine.
The Internal medicine study combines topics in areas such as Placebo and Type 2 Diabetes Mellitus.
His research on Type 2 diabetes focuses in particular on Empagliflozin.
Silvio E. Inzucchi has included themes like Cause of death and Hazard ratio in his Empagliflozin study.
His work in the fields of Intensive care unit overlaps with other areas such as In patient.
His most cited work include:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (5021 citations)
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (3586 citations)
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2433 citations)
What are the main themes of his work throughout his whole career to date?
Silvio E. Inzucchi mainly investigates Internal medicine, Diabetes mellitus, Type 2 diabetes, Cardiology and Empagliflozin.
Silvio E. Inzucchi has researched Internal medicine in several fields, including Placebo and Endocrinology.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Surgery, Insulin and Intensive care medicine.
His Type 2 diabetes research incorporates elements of Clinical trial, Kidney disease, Renal function, Disease and Type 2 Diabetes Mellitus.
In his study, which falls under the umbrella issue of Cardiology, Ischemia is strongly linked to Asymptomatic.
His Empagliflozin study incorporates themes from Standard of care, Blood pressure and Urology.
He most often published in these fields:
- Internal medicine (66.95%)
- Diabetes mellitus (47.67%)
- Type 2 diabetes (36.65%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (66.95%)
- Heart failure (17.58%)
- Empagliflozin (20.34%)
In recent papers he was focusing on the following fields of study:
Silvio E. Inzucchi spends much of his time researching Internal medicine, Heart failure, Empagliflozin, Diabetes mellitus and Cardiology.
His Internal medicine research integrates issues from Placebo and Type 2 diabetes, Dapagliflozin.
His Type 2 diabetes research also works with subjects such as
- Disease which connect with Intensive care medicine,
- Albuminuria which connect with Urinary system.
Silvio E. Inzucchi interconnects Kidney and Myocardial infarction in the investigation of issues within Empagliflozin.
Metformin is closely connected to Adverse effect in his research, which is encompassed under the umbrella topic of Diabetes mellitus.
As a part of the same scientific family, Silvio E. Inzucchi mostly works in the field of Cardiology, focusing on Stroke and, on occasion, Insulin resistance.
Between 2018 and 2021, his most popular works were:
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (1150 citations)
- A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). (92 citations)
- Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes (76 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Internal medicine, Heart failure, Diabetes mellitus, Cardiology and Dapagliflozin are his primary areas of study.
His work deals with themes such as Empagliflozin, Type 2 diabetes, Type 2 Diabetes Mellitus and Placebo, which intersect with Internal medicine.
His research in Type 2 diabetes intersects with topics in Odds ratio, Mace, Kidney disease and Renal function.
His Heart failure research includes elements of Hypoglycemia and Treatment outcome.
His Diabetes mellitus research incorporates themes from Adverse effect, Clinical trial, Randomized controlled trial and Myocardial infarction.
His Dapagliflozin research includes themes of Ejection fraction and Blood pressure.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
